Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada

Vancouver, British Columbia – May 16, 2025 – Onco-Innovations Limited (CSE: ONCO) (“Onco” or the “Company“) is pleased to announce that it will transfer the listing of its common shares (the “Common Shares”) to Cboe Canada Inc. (“Cboe Canada”) from the Canadian Securities Exchange (“CSE”). Onco expects its Common Shares to begin trading on Cboe Canada on May 22, 2025 under its existing ticker symbol “ONCO”, and the Company has submitted a request to voluntarily delist its Common Shares from the CSE, which is expected to take effect at the close of trading on May 21, 2025. No action is required from shareholders regarding this transition.

Cboe Canada, a Tier 1 stock exchange and part of the global Cboe Markets network, offers a robust and internationally recognized platform for innovative companies seeking investor trust, liquidity, and visibility. Since launching in 2015, Cboe Canada has supported issuers through advanced market infrastructure and access to real-time data solutions, including its ETF Market Canada platform—an institutional-grade resource for exploring and analyzing over 1,200 Canadian ETFs. Real-time quotes and market information on Onco-Innovations can be found at www.cboe.com.

“Our move to Cboe Canada is a pivotal step in Onco-Innovations’ journey as we scale our operations and deepen our commitment to developing impactful oncology solutions. This listing will not only enhance our visibility within the capital markets but also place us alongside a growing roster of forward-thinking companies focused on long-term value creation. We see this as an opportunity to broaden our investor base, strengthen engagement with institutions, and ensure that our capital strategy evolves in step with our scientific ambitions,” stated Thomas O’Shaughnessy, CEO of the Company.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco’s commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

Thomas O’Shaughnessy

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

The CSE and Cboe Canada have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the commencement of trading of the Common Shares on Cboe Canada, the Company’s request to voluntarily delist the Common Shares from the CSE, and the Company’s future goals and objectives. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain acts, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to transferring the Company’s listing of its Common Shares from the CSE to Cboe Canada, the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all. Accordingly, readers should not place undue reliance on any such forward-looking information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.